On/Off Therapeutics

On/Off Therapeutics (formerly Nutritheragene) is a French biotechnology company specializing in the development of switchable gene therapies. The company's core platform, Nutrireg® (also known as Nutriage), is a breakthrough technology that allows for the precise, reversible, and on-demand control of therapeutic gene expression in vivo. This system utilizes an artificial promoter that is activated by a specific, non-toxic dietary supplement, effectively providing a 'remote control' for gene therapy applications. The company primarily focuses on oncology and cellular immunotherapy, where managing the timing and dosage of gene expression is critical to reducing toxicity and improving therapeutic outcomes. By enabling the intermittent production of therapeutic proteins or RNAs, On/Off Therapeutics aims to overcome the limitations of traditional constitutive gene therapies, particularly in treating complex conditions like liver metastases and enhancing the efficacy of T-cell therapies.